Ryvu Therapeutics S.A. (RVU.WA)

PLN 36.5

(-3.95%)

Market Cap (In PLN)

843.72 Million

Revenue (In PLN)

46.86 Million

Net Income (In PLN)

-92.11 Million

Avg. Volume

4130.00

Currency
PLN
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
36.0-61.8
PE
-
EPS
-
Beta Value
0.648
ISIN
PLSELVT00013
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.
Employee Count
-
Website
https://www.ryvu.com
Ipo Date
2011-07-14
Details
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.